ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1223

Characterizing Rheumatoid Arthritis Patients by Their Biologic DMARD Prescription History

Piyam Das1, Sicong Huang2, Kumar Dahal2, Huahua Zheng3, Jonathan Coblyn2, Michael Weinblatt2, Tianxi Cai1 and Katherine Liao2, 1Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Harvard School of Public Health, Boston, MA

Meeting: ACR Convergence 2020

Keywords: Bioinformatics, Disease-Modifying Antirheumatic Drugs (Dmards), rheumatoid arthritis, TNF-blocking Antibody

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 8, 2020

Session Title: RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: IIn rheumatoid arthritis (RA), a patient’s biologic disease modifying anti-rheumatic drug (bDMARD) history and the duration of time they remain on each drug may provide an alternative approach to studying treatment efficacy.  Due to the complexity of these data, how to determine if patients are similar based on their past bDMARD use is challenging.  Bioinformatics methods designed to study genetic sequences are now available that cluster sequences by similarity.  In this proof of concept study, we applied and modified this bioinformatics approach to cluster RA patients by similar sequences of bDMARD prescriptions.

Methods: We studied patients from a validated electronic health record cohort of RA patients from two tertiary care centers and extracted data on all subjects who initiated a bDMARD 1/1/2008 through 07/31/2019.  Inclusion criteria included subjects with ≥6 months of data prior to 1/1/2008 and no bDMARD prescription.  The sequence of bDMARD for each subject was initiated with the 1st bDMARD prescription.  Sequences were defined by 5 bDMARD drug classes: tumor necrosis factor inhibitors (TNFi), CTLA4-Ig/abatacept, IL6R blockade/tocilizumab, JAK inhibitor/tofacitinib (small molecule grouped as bDMARD for this study), and anti-CD20/rituximab.  A change in bDMARD was defined as a change in bDMARD therapy ≥3 months from the prior bDMARD prescription.  A sequence by drug class was constructed for each subject.  The sequences were then analyzed using mixture Markov chain analysis. We consider the transitions of drug classes of a patient over the time as Markov chains where each of the drug classes was considered a state.  We clustered the patients based on the sequence of drug classes. We calculated descriptive statistics for demographics, and obtained the Charlson comorbidity index at the time of the 1st bDMARD prescription to compare across clusters.

Results: We studied 8684 RA subjects who initiated a bDMARD after 1/1/2008.  The mean age was 48.9 years, 73% female, 82% white, 68% seropositive, with mean follow-up time of 6.2 years; each subject had a unique sequence, thus there were 8684 sequences.  The sequences clustered in 4 main groups (Figure).  Descriptively, group 1 included patients who persisted on abatacept and tocilizumab therapy.  Group 2 contained patients on TNFi for the majority of their follow-up.  Group 3 contained a mixture of patients persisting on rituximab and TNFi.  Group 4 included patients who tried multiple bDMARDs for variable lengths of time.  The lowest % of females was observed in Group 2 (70%) compared to Group 4 (83%) which had the highest (p< 0.0001) (Table).  The highest % seropositive was observed in group 1 (80.5%) compared with group 2 (65%) which had the lowest (p< 0.0001).

Conclusion: Transforming bDMARD prescription histories into a sequence allowed us to cluster RA patients into 4 main groups which demonstrated differing clinical characteristics at the time of the 1st bDMARD prescription.  Future studies will examine whether the clinical profiles of patients in these clusters can be used to inform optimal bDMARD choices among RA patients prospectively.

Visualization of the 4 groups identified from clustering bDMARD sequences. Data from 75 random patients from each group shown with x-axis denoting the first 20 states (V1-V20) for each patient.

Comparison of clinical characteristics at the time of first bDMARD prescription across the 4 groups.


Disclosure: P. Das, None; S. Huang, None; K. Dahal, None; H. Zheng, None; J. Coblyn, None; M. Weinblatt, Crescendo Bioscience, 1, Bristol Myers Squibb, 1, Sanofi, 2, Lilly, 1, Amgen, 1, AbbVie, 5, Amgen, 2, 5, Arena, 5, Bristol Myers Squibb, 2, 5, Canfite, 1, 5, Corrona, 5, Crescendo, 2, 5, GlaxoSmithKline, 5, Gilead, 9, Horizon, 9, Johnson and Johnson, 9, Lilly, 2, 9, Pfizer, 9, Scipher, 1, 9, Set Point, 9, Roche, 9, Canfite, 1, Inmedix, 1, Lycera, 1, Vorso, 1, Scipher, 1; T. Cai, None; K. Liao, None.

To cite this abstract in AMA style:

Das P, Huang S, Dahal K, Zheng H, Coblyn J, Weinblatt M, Cai T, Liao K. Characterizing Rheumatoid Arthritis Patients by Their Biologic DMARD Prescription History [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/characterizing-rheumatoid-arthritis-patients-by-their-biologic-dmard-prescription-history/. Accessed April 14, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterizing-rheumatoid-arthritis-patients-by-their-biologic-dmard-prescription-history/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.